Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab bioavailability and combination with tirzepatide in healthy volunteers
NCT06890611Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bimagrumab (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at 16 weeks and Area Under the Curve from Zero to Infinity at 16 weeks. Started Mar 2025; status: completed.
02
Drugs
bimagrumab
Beyond the preview
Go deeper on NCT06890611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890611.